HER2 Therapy Market by Target Disease Indication, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030
The HER2 therapy market is expected to reach USD 441 million in 2021 and anticipated to grow at a CAGR of 8% during the forecast period 2021-2030.
Human epidermal growth factor receptor 2 (HER2), part of the human epidermal growth factor receptor family, plays a crucial role in the development and progression of various cancers, particularly breast cancer. It has become a significant focus for therapeutic interventions aimed at addressing different forms of breast cancer. Treatments targeting HER2 have shown significant promise in hindering tumor cells' ability to evade immune detection. A pivotal moment occurred in 1998 when the FDA approved the first HER2-targeting monoclonal antibody, known as Herceptin® (trastuzumab), for treating metastatic breast cancer. Later in 2006, its use was extended to early-stage HER2-positive breast cancer. This success prompted extensive research into its effectiveness in other conditions characterized by HER2 alterations, such as overexpression, amplifications, and mutations. In 2010, FDA approval was granted for HER2-positive metastatic stomach cancer. Apart from Herceptin, regulatory authorities have authorized over five drugs, with approximately 70 candidates in different developmental stages for various cancers including breast cancer, HER2-positive biliary tract, colorectal, non-small-cell lung, and gastric cancers. Additionally, studies combining HER2-targeting therapeutics with immune checkpoint inhibitors have shown promising results across different disease indications.
Currently, numerous entities, including established companies and emerging players, are actively engaged in developing HER2-targeting therapies tailored for various disease indications. The primary focus of innovation in this field revolves around enhancing therapeutic effectiveness, improving safety profiles, and increasing overall survival rates. Research efforts in this area have garnered significant attention and financial support from both private and public investors, supporting capable developer companies. Furthermore, the market has witnessed substantial collaborative initiatives in recent years. With the successes of existing drugs and HER2-targeted therapy products, along with promising outcomes from clinical trials, the market is poised for substantial growth. Anticipated approvals and subsequent market entries of multiple late-stage drugs are expected to drive this growth in the foreseeable future.
Report Coverage
Human epidermal growth factor receptor 2 (HER2), part of the human epidermal growth factor receptor family, plays a crucial role in the development and progression of various cancers, particularly breast cancer. It has become a significant focus for therapeutic interventions aimed at addressing different forms of breast cancer. Treatments targeting HER2 have shown significant promise in hindering tumor cells' ability to evade immune detection. A pivotal moment occurred in 1998 when the FDA approved the first HER2-targeting monoclonal antibody, known as Herceptin® (trastuzumab), for treating metastatic breast cancer. Later in 2006, its use was extended to early-stage HER2-positive breast cancer. This success prompted extensive research into its effectiveness in other conditions characterized by HER2 alterations, such as overexpression, amplifications, and mutations. In 2010, FDA approval was granted for HER2-positive metastatic stomach cancer. Apart from Herceptin, regulatory authorities have authorized over five drugs, with approximately 70 candidates in different developmental stages for various cancers including breast cancer, HER2-positive biliary tract, colorectal, non-small-cell lung, and gastric cancers. Additionally, studies combining HER2-targeting therapeutics with immune checkpoint inhibitors have shown promising results across different disease indications.
Currently, numerous entities, including established companies and emerging players, are actively engaged in developing HER2-targeting therapies tailored for various disease indications. The primary focus of innovation in this field revolves around enhancing therapeutic effectiveness, improving safety profiles, and increasing overall survival rates. Research efforts in this area have garnered significant attention and financial support from both private and public investors, supporting capable developer companies. Furthermore, the market has witnessed substantial collaborative initiatives in recent years. With the successes of existing drugs and HER2-targeted therapy products, along with promising outcomes from clinical trials, the market is poised for substantial growth. Anticipated approvals and subsequent market entries of multiple late-stage drugs are expected to drive this growth in the foreseeable future.
Report Coverage
- The report comprehensively examines the HER2 Therapy market, focusing on the route of administration, therapy type, molecule type, targeted disease indication, and geographic considerations.
- Analysis within the report delves into various factors, such as drivers, restraints, opportunities, and challenges impacting market growth.
- It evaluates potential advantages and obstacles present in the market, providing insights into the competitive landscape for leading market players.
- Revenue forecasts are provided for market segments across five major regions.
- A detailed examination of the current market landscape concerning HER2-targeting therapies is conducted. This includes analysis across multiple parameters such as developmental status, developmental phase, molecular type, biologic subtype, therapy type, targeted disease indication, therapeutic area, and administration route.
- The report offers a thorough analysis of completed, ongoing, and planned clinical trials for HER2-targeting therapies, highlighting trends across various parameters such as trial registration year, phase, patient population, study design, and regional distribution of trials.
- Elaborate company profiles engaged in developing HER2-targeting therapies encompass a company overview, product portfolio details, recent developments, and future outlook.
- In-depth analysis of grants awarded to research institutes for HER2-targeting therapy projects between 2018 and 2021, focusing on parameters like award year, funding amount, grant purpose, and geographical distribution.
- Examination of partnerships established between stakeholders in the HER2 therapy market between 2017 and 2021, covering various agreements and collaborations.
- Case studies on HER2-targeting biosimilars and companion diagnostic tests, reviewing the market landscape, developmental phases, target disease indications, and involved companies in their development.
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- MacroGenics
- Pfizer
- Puma Biotechnology
- Roche
- Seagen (previously Seattle Genetics)
- Triumvira Immunologics
- Zymeworks
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. HER2 Mutations
3.5. Overview of HER2 Targeting Therapies
3.5.1 Biologics Targeting HER2
3.5.1.1 Types of Products
3.5.2 Small Molecules Targeting HER2
3.5.2.1 Types of Products
3.6. Existing Challenges and Future Perspectives
4. CURRENT MARKET LANDSCAPE: MARKETED PRODUCTS AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. HER2 Targeting Therapies: Marketed Products and Development Pipeline
4.3. HER2 Targeting Therapies: Pipeline Analysis
4.3.1. Analysis by Current Status
4.3.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Route of Administration
4.3.8. Analysis by Phase of Development and Type of Molecule
4.3.9. Analysis by Phase of Development and Route of Administration
4.4. HER2 Targeting Therapies: Developer Landscape
4.4.1. Analysis by Type of Developer
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Geographical Location
4.4.5. Analysis by Company Size and Geographical Location
4.4.6. Leading Industry Players: Analysis by Number of Therapies
4.4.7. Leading Non-Industry Players: Analysis by Number of Therapies
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AstraZeneca
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. HER2 Targeting Therapies Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Boehringer Ingelheim
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. HER2 Targeting Therapies Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. GlaxoSmithKline
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. HER2 Targeting Therapies Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. MacroGenics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. HER2 Targeting Therapies Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Pfizer
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. HER2 Targeting Therapies Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Puma Biotechnology
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. HER2 Targeting Therapies Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Roche
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. HER2 Targeting Therapies Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. Seagen (previously Seattle Genetics)
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. HER2 Targeting Therapies Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. Triumvira Immunologics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. HER2 Targeting Therapies Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Zymeworks
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. HER2 Targeting Therapies Portfolio
5.11.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. HER2 Targeting Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase and Enrolled Patient Population
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Sponsor / Collaborator
6.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Disease Indication
6.3.10. Analysis by Target Therapeutic Area
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Enrolled Patient Population
7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. ` Scope and Methodology
7.3. HER2 Targeting Therapies: Analysis of Awarded Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Word Cloud Analysis: Emerging Focus Areas
7.3.10. Analysis by Study Section Involved
7.3.11. Popular NIH Departments: Analysis by Number of Grants Awarded
7.3.12. Prominent Program Officers: Analysis by Number of Grants Awarded
7.3.13. Analysis by Type of Recipient Organization
7.3.14. Popular Recipient Organizations: Analysis by Number of Grants Awarded
7.3.15. Regional Distribution of Recipient Organizations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. HER2 Targeting Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.4. Regional Analysis
8.4.1. Intercontinental and Intracontinental Agreements
9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global HER2 Targeting Therapies Market, 2021-2031
9.4. HER2 Targeting Therapies: Individual Product Sales Forecasts
9.4.1. BAT8001 (Bio-Thera Solutions)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast
9.4.2. ENHERTU® (AstraZeneca)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast
9.4.3. Gilotrif® (Boehringer Ingelheim)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast
9.4.4. KADCYLA™ (Roche)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast
9.4.5. MARGENZA™ (MacroGenics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast
9.4.6. RC48 (RemeGen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast
9.4.7. Nerlynx™ (Puma Biotechnology)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast
9.4.8. Perjeta® (Genentech, a Roche’s company)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast
9.4.9. SYD985 (Byondis)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast
9.4.10. MOBOCERTINIB (Takeda)
9.4.10.1. Target Patient Population
9.4.10.2. Sales Forecast
9.4.11. Tukysa® (Seagen)
9.4.11.1. Target Patient Population
9.4.11.2. Sales Forecast
9.4.12. Tyverb® (Roche)
9.4.12.1. Target Patient Population
9.4.12.2. Sales Forecast
9.4.13. Vizimpro® (Pfizer)
9.4.13.1. Target Patient Population
9.4.13.2. Sales Forecast
9.5. Global HER2 Targeting Therapies Market, 2021-2031: Distribution by Geography
9.5.1. HER2 Targeting Therapies Market in the North America, 2021-2031
9.5.2. HER2 Targeting Therapies Market in Europe, 2021-2031
9.5.3. HER2 Targeting Therapies Market in Asia Pacific, 2021-2031
9.5.4. HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031
9.5.5. HER2 Targeting Therapies Market in Latin America, 2021-2031
9.6. Global HER2 Targeting Therapies Market: Distribution by Target Disease Indication
9.6.1. Global HER2 Targeting Therapies Market for Breast Cancer, 2021-2031
9.6.2. Global HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031
9.6.3. Global HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031
9.6.4. Global HER2 Targeting Therapies Market for Lung Cancer, 2021-2031
9.7. Global HER2 Targeting Therapies Market: Distribution by Type of Molecule
9.7.1. Global HER2 Targeting Therapies Market for Biologics, 2021-2031
9.7.2. Global HER2 Targeting Therapies Market for Small Molecules, 2021-2031
9.8. Global HER2 Targeting Therapies Market: Distribution by Type of Therapy
9.8.1. Global HER2 Targeting Therapies Market for Monotherapy, 2021-2031
9.8.2. Global HER2 Targeting Therapies Market for Combination Therapy, 2021-2031
9.8.3. Global HER2 Targeting Therapies Market for Both Therapies, 2021-2031
9.9. Global HER2 Targeting Therapies Market: Distribution by Route of Administration
9.9.1. Global HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031
9.9.2. Global HER2 Targeting Therapies Market for Oral Therapies, 2021-2030
10. CASE STUDY: HER2 TARGETING BIOSIMILARS
10.1. Chapter Overview
10.2. HER2 Targeting Biosimilars: Marketed Products and Development Pipeline
10.3. HER2 Targeting Biosimilars: Pipeline Analysis
10.3.1. Analysis by Parent Drug
10.3.2. Analysis by Phase of Development of Biosimilar
10.3.3. Analysis by Target Disease Indication
10.4. HER2 Targeting Biosimilars: Developer Landscape
10.4.1. Analysis by Year of Establishment
10.4.2. Analysis by Geographical Location
10.4.3. Analysis by Company Size and Geographical Location
11. CASE STUDY: COMPANION DIAGNOSTICS FOR HER2 TARGETING THERAPIES
11.1. Chapter Overview
11.2. Companion Diagnostics for HER2 Targeting Therapies
11.2.1. Analysis by Commercial Availability of the Test
11.2.2. Analysis by Assay Technique Used
11.2.3. Analysis by Corresponding Drug Candidate
11.2.4. Analysis by Target Disease Indication
11.3. Companion Diagnostics for HER2 Targeting Therapies: Developer Overview
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Geographical Location
12. CONCLUDING REMARKS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. HER2 Mutations
3.5. Overview of HER2 Targeting Therapies
3.5.1 Biologics Targeting HER2
3.5.1.1 Types of Products
3.5.2 Small Molecules Targeting HER2
3.5.2.1 Types of Products
3.6. Existing Challenges and Future Perspectives
4. CURRENT MARKET LANDSCAPE: MARKETED PRODUCTS AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. HER2 Targeting Therapies: Marketed Products and Development Pipeline
4.3. HER2 Targeting Therapies: Pipeline Analysis
4.3.1. Analysis by Current Status
4.3.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Route of Administration
4.3.8. Analysis by Phase of Development and Type of Molecule
4.3.9. Analysis by Phase of Development and Route of Administration
4.4. HER2 Targeting Therapies: Developer Landscape
4.4.1. Analysis by Type of Developer
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Geographical Location
4.4.5. Analysis by Company Size and Geographical Location
4.4.6. Leading Industry Players: Analysis by Number of Therapies
4.4.7. Leading Non-Industry Players: Analysis by Number of Therapies
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AstraZeneca
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. HER2 Targeting Therapies Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Boehringer Ingelheim
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. HER2 Targeting Therapies Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. GlaxoSmithKline
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. HER2 Targeting Therapies Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. MacroGenics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. HER2 Targeting Therapies Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Pfizer
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. HER2 Targeting Therapies Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Puma Biotechnology
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. HER2 Targeting Therapies Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Roche
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. HER2 Targeting Therapies Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. Seagen (previously Seattle Genetics)
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. HER2 Targeting Therapies Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. Triumvira Immunologics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. HER2 Targeting Therapies Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Zymeworks
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. HER2 Targeting Therapies Portfolio
5.11.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. HER2 Targeting Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase and Enrolled Patient Population
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Sponsor / Collaborator
6.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Disease Indication
6.3.10. Analysis by Target Therapeutic Area
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Enrolled Patient Population
7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. ` Scope and Methodology
7.3. HER2 Targeting Therapies: Analysis of Awarded Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Word Cloud Analysis: Emerging Focus Areas
7.3.10. Analysis by Study Section Involved
7.3.11. Popular NIH Departments: Analysis by Number of Grants Awarded
7.3.12. Prominent Program Officers: Analysis by Number of Grants Awarded
7.3.13. Analysis by Type of Recipient Organization
7.3.14. Popular Recipient Organizations: Analysis by Number of Grants Awarded
7.3.15. Regional Distribution of Recipient Organizations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. HER2 Targeting Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.4. Regional Analysis
8.4.1. Intercontinental and Intracontinental Agreements
9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global HER2 Targeting Therapies Market, 2021-2031
9.4. HER2 Targeting Therapies: Individual Product Sales Forecasts
9.4.1. BAT8001 (Bio-Thera Solutions)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast
9.4.2. ENHERTU® (AstraZeneca)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast
9.4.3. Gilotrif® (Boehringer Ingelheim)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast
9.4.4. KADCYLA™ (Roche)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast
9.4.5. MARGENZA™ (MacroGenics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast
9.4.6. RC48 (RemeGen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast
9.4.7. Nerlynx™ (Puma Biotechnology)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast
9.4.8. Perjeta® (Genentech, a Roche’s company)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast
9.4.9. SYD985 (Byondis)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast
9.4.10. MOBOCERTINIB (Takeda)
9.4.10.1. Target Patient Population
9.4.10.2. Sales Forecast
9.4.11. Tukysa® (Seagen)
9.4.11.1. Target Patient Population
9.4.11.2. Sales Forecast
9.4.12. Tyverb® (Roche)
9.4.12.1. Target Patient Population
9.4.12.2. Sales Forecast
9.4.13. Vizimpro® (Pfizer)
9.4.13.1. Target Patient Population
9.4.13.2. Sales Forecast
9.5. Global HER2 Targeting Therapies Market, 2021-2031: Distribution by Geography
9.5.1. HER2 Targeting Therapies Market in the North America, 2021-2031
9.5.2. HER2 Targeting Therapies Market in Europe, 2021-2031
9.5.3. HER2 Targeting Therapies Market in Asia Pacific, 2021-2031
9.5.4. HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031
9.5.5. HER2 Targeting Therapies Market in Latin America, 2021-2031
9.6. Global HER2 Targeting Therapies Market: Distribution by Target Disease Indication
9.6.1. Global HER2 Targeting Therapies Market for Breast Cancer, 2021-2031
9.6.2. Global HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031
9.6.3. Global HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031
9.6.4. Global HER2 Targeting Therapies Market for Lung Cancer, 2021-2031
9.7. Global HER2 Targeting Therapies Market: Distribution by Type of Molecule
9.7.1. Global HER2 Targeting Therapies Market for Biologics, 2021-2031
9.7.2. Global HER2 Targeting Therapies Market for Small Molecules, 2021-2031
9.8. Global HER2 Targeting Therapies Market: Distribution by Type of Therapy
9.8.1. Global HER2 Targeting Therapies Market for Monotherapy, 2021-2031
9.8.2. Global HER2 Targeting Therapies Market for Combination Therapy, 2021-2031
9.8.3. Global HER2 Targeting Therapies Market for Both Therapies, 2021-2031
9.9. Global HER2 Targeting Therapies Market: Distribution by Route of Administration
9.9.1. Global HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031
9.9.2. Global HER2 Targeting Therapies Market for Oral Therapies, 2021-2030
10. CASE STUDY: HER2 TARGETING BIOSIMILARS
10.1. Chapter Overview
10.2. HER2 Targeting Biosimilars: Marketed Products and Development Pipeline
10.3. HER2 Targeting Biosimilars: Pipeline Analysis
10.3.1. Analysis by Parent Drug
10.3.2. Analysis by Phase of Development of Biosimilar
10.3.3. Analysis by Target Disease Indication
10.4. HER2 Targeting Biosimilars: Developer Landscape
10.4.1. Analysis by Year of Establishment
10.4.2. Analysis by Geographical Location
10.4.3. Analysis by Company Size and Geographical Location
11. CASE STUDY: COMPANION DIAGNOSTICS FOR HER2 TARGETING THERAPIES
11.1. Chapter Overview
11.2. Companion Diagnostics for HER2 Targeting Therapies
11.2.1. Analysis by Commercial Availability of the Test
11.2.2. Analysis by Assay Technique Used
11.2.3. Analysis by Corresponding Drug Candidate
11.2.4. Analysis by Target Disease Indication
11.3. Companion Diagnostics for HER2 Targeting Therapies: Developer Overview
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Geographical Location
12. CONCLUDING REMARKS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
